Grepid 75mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Clopidogrel

Available from:

Kent Pharmaceuticals Ltd

ATC code:

B01AC04

INN (International Name):

Clopidogrel

Dosage:

75mg

Pharmaceutical form:

Tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02090000; GTIN: 5060061160650 5060061160773

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
GREPID 75 MG FILM-COATED TABLETS
clopidogrel
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or your
pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on
to others. It may harm them, even if their signs of illness are the
same as yours.
-
If you have any side effects, including any side effects not listed in
this leaflet, talk to your doctor or pharmacist. See section 4.
WHAT IS IN THIS LEAFLET
1. What Grepid is and what it is used for
2. What you need to know before you take Grepid
3. How to take Grepid
4. Possible side effects
5. How to store Grepid
6. Contents of the pack and other information
1. W
HAT
G
REPID IS AND WHAT IT IS USED FOR
Grepid contains clopidogrel and belongs to a group of medicines
called antiplatelet medicinal products. Platelets are very small
structures in the blood which clump together during blood clotting. By
preventing this clumping, antiplatelet medicinal products reduce the
chances of blood clots forming (a process called thrombosis).
Grepid is taken by adults to prevent blood clots (thrombi) forming in
hardened blood vessels (arteries), a process known as
atherothrombosis, which can lead to atherothrombotic events (such
as stroke, heart attack or death).
You have been prescribed Grepid to help prevent blood clots and
reduce the risk of these severe events because:
-
you have a condition of hardening of arteries (also known as
atherosclerosis), and
-
you have previously experienced a heart attack, stroke or have a
condition known as peripheral arterial disease, or
-
You have experienced a severe type of chest pain known as
‘unstable angina’ or ‘myocardial infarction’ (heart attack).
For the
treatment of this condition your doctor may have placed a stent in
the blocked or narrowed artery to restore effective blood flow. You
should

Summary of Product characteristics

OBJECT 1
GREPID (CLOPIDOGREL) 75MG TABLETS X 30
Summary of Product Characteristics Updated 30-Apr-2014 | Beacon
Pharmaceuticals
1. Name of the medicinal product
Grepid 75 mg film-coated tablets
2. Qualitative and quantitative composition
Each film-coated tablet contains 75 mg of clopidogrel (as besilate).
Excipients with known effect:
Each film-coated tablet contains 2.47 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet.
Pink, round, biconvex, film-coated tablets.
4. Clinical particulars
4.1 Therapeutic indications
_Prevention of atherothrombotic events_
Clopidogrel is indicated in:
• Adult patients suffering from myocardial infarction (from a few
days until less than 35 days), ischaemic
stroke (from 7 days until less than 6 months) or established
peripheral arterial disease.
• Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave myocardial
infarction), including patients undergoing a stent placement following
percutaneous coronary
intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination
with ASA in medically treated
patients eligible for thrombolytic therapy.
_Prevention of atherothrombotic and thromboembolic events in atrial
fibrillation_
In adult patients with atrial fibrillation who have at least one risk
factor for vascular events, are not
suitable for treatment with Vitamin K antagonists (VKA) and who have a
low bleeding risk, clopidogrel
is indicated in combination with ASA for the prevention of
atherothrombotic and thromboembolic events,
including stroke.
For further information please refer to section 5.1.
4.2 Posology and method of administration
Posology
• Adults and older people
Clopidogrel should be given as a single daily dose of 75 mg.
In patients suffering from acute coronary syndrome:
− Non-ST segment elevation acute coronary syndrome (unstable angina
or non-Q-w